Notably, the correlation between higher lymphocyte counts and responses to multiple TAA-specific CD8+ T-cells with prolonged overall survival accentuates the critical role of KIF20A as a target for immunotherapy, thereby enriching the immunotherapeutic arsenal against cholangiocarcinoma and potentially other cancers [104]. This evidence concerns the gene CD8A and cholangiocarcinoma.